Page last updated: 2024-08-24

vorozole and mk 2206

vorozole has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE	1

Other Studies

1 other study(ies) available for vorozole and mk 2206

Article	Year
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models. Oncology reports, 2018, Volume: 40, Issue:3 Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles	2018

Article

Year

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

Oncology reports, 2018, Volume: 40, Issue:3

Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles

2018